Respiratory Clinical Trials

Statistical methods in respiratory trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All respiratory trials

865 results

• REACT AsthmaIndependent statistical analysis of REACT Asthma (NCT06299306), a registry study evaluating asthma control using the Asthma Impairment and Risk Questionnaire (AIRQ®) over 12 months.n = 19NCT06299306
• Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients – A Multi Center Chart Review: Complete Statistical AnalysisIndependent statistical analysis of Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review:…Phase NAResults postedn = 307NCT04609319
• RECOVERYIndependent statistical analysis of the RECOVERY phase 3 trial, including its factorial design, primary mortality and time-to-discharge endpoints, planned statistical methods, and interpretation of the trial design.Phase 3n = 70,000NCT04381936
• REDEFINEIndependent statistical analysis of Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 402NCT03137303
• Relative Bioavailability of of Olodaterol and Ketoconazole: Complete Statistical AnalysisIndependent statistical analysis of Relative Bioavailability of of Olodaterol and Ketoconazole: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01153711).Phase 1Results postedn = 32NCT01153711
• Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants: Complete Statistical AnalysisIndependent statistical analysis of Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 29NCT04095286
• Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 1Results postedn = 15NCT05525910
• Reliability of Consumer Sleep Trackers in Patients Suffering From Obstructive Sleep Apnea Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Reliability of Consumer Sleep Trackers in Patients Suffering From Obstructive Sleep Apnea Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 36NCT02967367
• REMAP-CAPAn independent statistical analysis of REMAP-CAP, the randomized phase 3 multifactorial adaptive platform trial evaluating multiple treatment strategies in community-acquired pneumonia, influenza, and COVID-19.Phase 3n = 20,000NCT02735707
• RESPIRE 1Independent statistical analysis of RESPIRE 1, a randomized phase 3 trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis, including time-to-exacerbation and exacerbation-rate analyses.Phase 3Results postedn = 416NCT01764841
• RESPIRE 1Independent statistical analysis of Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 416NCT01764841
• RestorAATion-1Independent statistical analysis of A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1): primary endpoint results, effect estimate with confidence…Phase 1Results postedn = 47NCT06186492
• RESTOREIndependent statistical analysis of A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 9NCT04435782
• REVIRAL 1Independent statistical analysis of A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 51NCT04225897
• RIFASHORTIndependent statistical analysis of the RIFASHORT phase 3 trial evaluating 1200mg and 1800mg rifampicin for pulmonary tuberculosis, including trial design, endpoints, planned statistical methods, and interpretation.Phase 3n = 672NCT02581527
• RISE-IIPComplete statistical analysis of RISE-IIP, the randomized phase 2 trial of riociguat versus placebo in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias.Phase 2Results postedn = 147NCT02138825
• SAFEIndependent statistical analysis of Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH): primary endpoint results, effect estimate with confidence interval,…Phase NAResults postedn = 411NCT00358735
• SAPPHIREIndependent statistical analysis of Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 577NCT03906071
• SAR-COVIDIndependent statistical analysis of SAR-COVID (NCT04357808), a randomized phase 2 trial evaluating subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection.Phase 2n = 30NCT04357808
• SARCAIndependent statistical analysis of Lansoprazole to Treat Children With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00442013).Phase 4Results postedn = 306NCT00442013
• SCORPIO-HRComplete statistical analysis of the SCORPIO-HR phase 3 trial of S-217622 (ensitrelvir) versus placebo in non-hospitalized participants with SARS-CoV-2 infection, including trial design, time to sustained symptom resolution, restricted mean symptom duration,…Phase 3Results postedn = 2,093NCT05305547
• SDTTIndependent statistical analysis of Assessment of Laryngopharyngeal Sensation in Adductor Spasmodic Dysphonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05158179).Phase NAResults postedn = 13NCT05158179
• SELECT-3Independent statistical analysis of Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence…Phase 1Results postedn = 55NCT01809210
• SERAPHINIndependent statistical analysis of SERAPHIN, the randomized phase 3 trial of macitentan in symptomatic pulmonary arterial hypertension, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, and interpretation.Phase 3Results postedn = 742NCT00660179
• SHAREDCareIndependent statistical analysis of Assessing and Addressing Follow-up Care Needs That Will Facilitate Care Transitions for Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 5NCT06654245
• SICAS-1Independent statistical analysis of Allergens in Inner-City Schools and Childhood Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01756391).Phase NAResults postedn = 351NCT01756391
• SIMAPIndependent statistical analysis of Pictograms to Facilitate Comprehension of Medical Indications: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05609760).Phase NAResults postedn = 22NCT05609760
• SMA-TBIndependent statistical analysis of Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04575519).Phase 2Results postedn = 426NCT04575519
• SMARTIndependent statistical analysis of SMART (NCT02477397), a randomized phase 3 trial comparing Spiromax budesonide/formoterol with Diskus fluticasone/salmeterol in COPD, including its design, symptom endpoint, planned analysis, and statistical interpretation.Phase 3n = 201NCT02477397
• SOMNOSIndependent statistical analysis of Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01503164).Phase NAResults postedn = 111NCT01503164
• SPIN-CHATIndependent statistical analysis of Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 172NCT04335279
• SPIROMICSIndependent statistical analysis of SPIROMICS (NCT01969344), a longitudinal study of COPD subgroups, biomarkers, lung function, imaging, environmental exposures, and disease progression.n = 2,981NCT01969344
• STARTIndependent statistical analysis of Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02097641).Phase 2Results postedn = 60NCT02097641
• STEP-IPFIndependent statistical analysis of STEP-IPF (NCT00517933), a randomized phase 3 trial of sildenafil versus placebo in patients with pulmonary fibrosis and pulmonary hypertension, including endpoint definitions, reported statistical analyses, interpretation, and limitations.Phase 3Results postedn = 180NCT00517933
• STOICIndependent statistical analysis of the randomized phase 2 STOIC trial evaluating budesonide dry powder inhaler in coronavirus infection, including trial design, the primary endpoint, planned statistical analysis, and interpretation.Phase 2n = 146NCT04416399
• SUN1058Independent statistical analysis of A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 162NCT00265317
• SUPERNOVAIndependent statistical analysis of the randomized phase 2/3 SUPERNOVA trial of AZD3152 and AZD7442 for prevention of COVID-19, including non-inferiority, superiority, Poisson regression, ANOVA, safety, and interpretation of reported results.Phase 2/3Results postedn = 3,882NCT05648110
• SURMOUNT-OSAIndependent statistical analysis of SURMOUNT-OSA, a randomized phase 3 trial of tirzepatide in participants with obstructive sleep apnea and obesity, including AHI results, ANCOVA, logistic regression, confidence intervals, and safety.Phase 3Results postedn = 469NCT05412004
• SWARM-PaIndependent statistical analysis of Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis: primary endpoint results, effect estimate with confidence…Phase 1/2Results postedn = 29NCT04596319
• SWIFT-1Independent statistical analysis of Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 395NCT04719832
• SYGMA2Complete statistical analysis of SYGMA2, a randomized phase 3 trial evaluating as-needed budesonide/formoterol versus twice-daily budesonide with as-needed terbutaline in adults and adolescents with asthma.Phase 3Results postedn = 4,215NCT02224157
• SYMPHONYextIndependent statistical analysis of Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 4NCT01847014
• Synagis RussiaIndependent statistical analysis of A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and…Phase 3Results postedn = 50NCT02968173
• TALCIndependent statistical analysis of Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC):…Phase 3Results postedn = 210NCT00565266
• TAS3351Independent statistical analysis of A Study of TAS3351 in NSCLC Patients With EGFRmt: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05765734).Phase 1Results postedn = 18NCT05765734
• TBTC Study 22An independent statistical analysis and educational interpretation of TBTC Study 22, a randomized phase 3 trial evaluating rifapentine and isoniazid in pulmonary tuberculosis.Phase 3n = 1,000NCT00023335
• TeenCoveComplete statistical analysis of the TeenCove trial of mRNA-1273 and mRNA-1273.222 in adolescents 12 toPhase 2/3Results postedn = 4,328NCT04649151
• TIDE-asthmaIndependent statistical analysis of Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 437NCT05421598
• TITREIndependent statistical analysis of Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00710866).Phase 3Results postedn = 262NCT00710866
• TOP 1501Independent statistical analysis of Neoadjuvant Pembrolizumab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02818920).Phase 2Results postedn = 35NCT02818920

← All therapeutic areas